Ribocil

Ribocil is a selective inhibitor targeting the bacterial FMN riboswitch, regulating the bacterial riboflavin riboswitch. Ribocil competitively binds to the FMN binding site, mimicking the natural ligand FMN to induce conformational changes in the riboswitch, inhibiting ribB gene expression, reducing riboflavin synthesis, and thus inhibiting bacterial growth. Ribocil strongly inhibits GFP expression (EC50=0.3 μM) . Ribocil exhibits in vivo antibacterial activity in a mouse model and can be used to study antibacterial drugs related to drug-resistant bacterial infections and bacterial riboflavin metabolic pathways[1][2].

Product Specifications

CAS Number

[1381289-58-2]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Ribocil.html

Purity

99.58

Solubility

DMSO : 12.5 mg/mL (ultrasonic)

Smiles

C1(C=C(NC(=N1)C1CN(CC2C=NC(NC)=NC=2)CCC1)C1=CC=CS1)=O

Molecular Formula

C19H22N6OS

Molecular Weight

382.48

Precautions

H302, H315, H319, H335

References & Citations

[1]Howe JA, et al. Selective small-molecule inhibition of an RNA structural element. Nature. 2015 Oct 29;526 (7575) :672-7.|[2]Howe JA, et al. Atomic resolution mechanistic studies of ribocil: A highly selective unnatural ligand mimic of the E. coli FMN riboswitch. RNA Biol. 2016 Oct 2;13 (10) :946-954.